InTandem Capital Partners
InTandem Capital Partners is a healthcare-focused private equity firm investing in lower-middle-market services businesses.
- Healthcare and life sciences private equity investment firm
- Healthcare & Life Sciences PEF
- Tier III
Overview
InTandem Capital Partners is a healthcare-focused private equity firm investing in lower-middle-market services businesses. Its portfolio has included provider platforms, specialty care, payer-related services, and other companies positioned to improve healthcare delivery.
The firm combines capital with operating resources and healthcare executive relationships. Its strategy often involves working with management teams to build regional or national platforms through organic development, acquisitions, and stronger operating infrastructure. Within The Economy Wiki, the firm is connected to the Healthcare & Life Sciences PEF market category.
Firm facts
| Institution | InTandem Capital Partners |
| Type | Healthcare and life sciences private equity investment firm |
| Headquarters | New York, United States |
| Founded | 2011 |
| Primary ranking focus | Healthcare & Life Sciences PEF |
| Highest 2026 tier | Tier III |
Activities and investment capabilities
Site-of-care changes and demand for specialized outpatient services create opportunities for this model, but they also require disciplined attention to clinician alignment, reimbursement, regulatory compliance, patient experience, and local market execution.
Healthcare investing
Equity investment across healthcare services, products and technology.
Life sciences exposure
Capital for pharmaceutical, biotechnology, medtech and outsourced-service platforms.
Sector value creation
Support informed by regulation, reimbursement, clinical workflows and market access.
Strategy and transaction coverage
Strategy and sector coverage
Healthcare services; life sciences; pharmaceuticals; medtech; diagnostics; healthcare IT
Transaction and ownership contexts
Buyouts; growth investments; recapitalizations; platform formation; add-on acquisitions
Market position
InTandem Capital Partners fits Tier III because it is an established healthcare services specialist with a clear platform-building identity, while its scale and subsector range remain more concentrated than those of the upper-tier firms.
InTandem Capital Partners is assessed within the Healthcare & Life Sciences PEF framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
InTandem Capital Partners is recognized Tier III in Top 30 Healthcare & Life Sciences PEF 2026. The ranking compares firms by institutional relevance, specialist capability, investment activity, operating depth and market positioning. Comparable-firm links below support navigation and do not imply that every institution competes for every transaction or asset.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through InTandem Capital Partners’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to InTandem Capital Partners as the public-facing investment organization. Individual funds, management companies, advisers and regulated entities may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | InTandem Capital Partners |
| Headquarters | New York, United States |
| Public website | intandemcapital.com |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the investment, diligence, financing and value-creation themes relevant to this firm:
- The Mid-Market Advantage in Healthcare Private Equity
- Middle-Market Private Equity: Returns, Scale and Manager Selection
- Private Equity Technology Due Diligence in the AI Era
